The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Surfaceome profiling to reveal unique therapeutic vulnerabilities in transcriptional subtypes of small cell lung cancer (SCLC).
 
Taofeek K. Owonikoko
Stock and Other Ownership Interests - CAMBIUM MEDICAL TECHNOLOGIES; Taobob LLC
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; BeiGene; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Coherus Biosciences; Daichi; Eisai; Eisai; EMD Serono; Exelixis; G1 Therapeutics; Ipsen; Janssen; Jazz Pharmaceuticals; Lilly; MedImmune; Merck; Novartis; PharmaMar; Roche/Genentech; Takeda; Triptych Health Partners; Wells Fargo; Xcovery; Xcovery; Zentalis
Speakers' Bureau - Abbvie
Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Corvus Pharmaceuticals; Eisai (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Loxo/Lilly (Inst); Merck (Inst); Mersana (Inst); Meryx Pharmaceuticals (Inst); Novartis (Inst); Oncorus (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst); Turning Point Therapeutics (Inst); United Therapeutics (Inst); WindMIL (Inst)
Patents, Royalties, Other Intellectual Property - DR4 Modulation and its Implications in EGFR-Target Cancer Therapy Ref:18089 PROV (CSP) United States Patent Application No. 62/670,210 June 26, 2018 (Co-Inventor) (Inst); OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst); Soluble FAS ligand as a biomarker of recurrence in thyroid cancer; provisional patent 61/727,519 (Inventor) (Inst)
Other Relationship - EMD Serono; Novartis; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Reflexion Medical
 
Andrew Elliott
Employment - Caris Life Sciences
 
Bhakti Dwivedi
No Relationships to Disclose
 
Andrey Ivanov
No Relationships to Disclose
 
Gabriel Sica
No Relationships to Disclose
 
Sonam Puri
Consulting or Advisory Role - AstraZeneca (Inst); G1 Therapeutics (Inst)
 
Abdul Rafeh Naqash
No Relationships to Disclose
 
Kathleen Claire Kerrigan
Stock and Other Ownership Interests - bristol myers squibb (I)
Consulting or Advisory Role - Quality Fieldwork Associates
Travel, Accommodations, Expenses - Flatiron Health
 
Shiven B. Patel
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Regeneron; Sanofi; Tersera; Total Health Conferencing
Research Funding - AstraZeneca (Inst); Janssen (Inst); Merck (Inst); Takeda (Inst)
 
Andreas Seeber
Consulting or Advisory Role - Caris Life Sciences
Travel, Accommodations, Expenses - Caris Life Sciences
 
Florian Kocher
No Relationships to Disclose
 
Dipesh Uprety
No Relationships to Disclose
 
Hirva Mamdani
Consulting or Advisory Role - MorphoSys (I); Seagen (I); Zentalis
 
Amit Kulkarni
Stock and Other Ownership Interests - Exact Sciences; Exact Sciences; Fate Therapeutics; Gilead Sciences; Merck; Mirati Therapeutics; Novavax
 
Gilberto Lopes
Stock and Other Ownership Interests - Lucence Diagnostics; Xilis
Honoraria - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Merck
Consulting or Advisory Role - AstraZeneca; Pfizer
Research Funding - Abbvie (Inst); adaptimmune (Inst); AstraZeneca; AstraZeneca (Inst); Bavarian Nordic (Inst); Blueprint Medicines (Inst); BMS (Inst); E.R. Squibb Sons, LLC; EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Lucence; Lucence; Merck Sharp & Dohme (Inst); NOVARTIS (Inst); Pfizer (Inst); Rgenix (Inst); Roche (Inst); Tesaro (Inst); Xilis
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Celgene; E.R. Squibb Sons, LLC; Ipsen; Janssen; Merck; Pfizer; Pharmacyclics; Seagen; Seagen
Other Relationship - Mirati Therapeutics
 
Balazs Halmos
Consulting or Advisory Role - Apollomics; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Foundation Medicine; Genentech/Roche; Guardant Health; Janssen Oncology; Lilly; Merck; Novartis; Pfizer; Spectrum Pharmaceuticals; Takeda; Turning Point Therapeutics; Veracyte
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen; AstraZeneca (Inst); BeiGene; Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Elevation Oncology; GlaxoSmithKline (Inst); Guardant Health (Inst); Janssen Oncology (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
 
Wallace L. Akerley
No Relationships to Disclose
 
Stephen V Liu
No Relationships to Disclose
 
Wolfgang Michael Korn
Employment - Caris Life Sciences
Leadership - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
 
Hossein Borghaei
Stock and Other Ownership Interests - Nucleai; Rgenix; Sonnet
Honoraria - Amgen; Axiom Biotechnologies; Bristol-Myers Squibb; Celgene; Pfizer
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Beigene; BioNTech; Boehringer Ingelheim; Bristol-Myers Squibb; Cantargia AB; Celgene; EMD Serono; Genentech; Genmab; Guardant Health; HUYA Bioscience International; Jazz Pharmaceuticals; Lilly; Merck; Mirati Therapeutics; Novartis; Pfizer; PharmaMar; Regeneron; Rgenix; Sonnet; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Lilly; Merck; Novartis
Other Relationship - Incyte; Takeda; University of Pennsylvania